Zolefix 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Zolefix 100 is effective against infections caused by dermatophytes, yeasts, and molds, including conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. The capsule formulation ensures optimal bioavailability when administered orally, with absorption enhanced by acidic gastric pH. Dosage and duration of therapy should be tailored based on the severity and type of infection, with careful monitoring for potential adverse effects such as hepatotoxicity, gastrointestinal disturbances, and drug interactions due to itraconazole’s inhibition of CYP3A4 enzymes. Contraindications include hypersensitivity to itraconazole or other azoles and concurrent use with certain medications that may cause serious interactions. Zolefix 100 Capsule should be used under medical supervision to ensure efficacy and safety in managing fungal infections.